Αποτελέσματα Αναζήτησης
Download PDF Guideline Development Process ... Gersz EM, Leininger E, Zanitsch H, Yonker M, Mack K. (2019) Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache ...
The International Classification of Headache Disorders gives useful descriptions and diagnostic criteria that are especially useful for primary headaches. The National Institute for Health and Care Excellence (NICE) Clinical Guideline 150 provides evidence-based recommendations on treatments for adults and young people from age 12 years.
This guideline, for use by primary care providers, explains the evaluation, treatment, and referral process for children and adolescents (ages 3-21 years) whose chief complaint is headache.
Headache is very common in children and young people. The correct advice and treatment requires consideration of a wide differential diagnosis between primary and secondary headaches, and also of the different types of primary headache.
1 Δεκ 2012 · Educational Gap: Headaches are common in children; while most are caused by a benign problem or primary headache disorder, headaches can be a sign of a serious underlying condition.
Sumatriptan 10 mg and zolmitriptan 5 mg as nasal spray are approved for the treatment of migraine in adolescents age 12 or older. In triptan studies, the high placebo response and the short duration of attacks were methodical problems in showing efficacy of triptans in children under the age of 12 years.
migraine treatments in children and adolescents. The guide-line seeks to answer the following clinical question: In children and adolescents with migraine, do acute self-administered treatments, compared with placebo, reduce headache pain and associated symptoms (nausea, vomiting, photophobia, and phonophobia) and maintain headache freedom?
